FDA approvals and indications Nucala is approved: as an add-on maintenance treatment of severeasthmawith an eosinophilic phenotype in adults and children aged 6 years and older. It is not a rescue medicine for acute bronchospasm or status asthmaticus ...
FDA approval history Drug class: interleukin inhibitors Breastfeeding En español Patient resources Nucala drug information Professional resources Nucala prescribing information Mepolizumab (AHFS Monograph) Related treatment guides Chronic Rhinosinusitis With Nasal Polyps Hypereosinophilic Syndrome Eosinophilic Granu...
GSK today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab)
In September 2020, the U.S. Food and Drug Administration (FDA) announced the approval of Nucala (mepolizumab) for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for 6 months or longer without another identifiable non-hematologic secondar...
Advise the patient to read the FDA-approved patient labeling (PATIENT INFORMATION and Instructions for Use). Hypersensitivity Reactions Inform patients that hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred after administration of NUCALA. In...